In a double-blind crossover trial, carbamazepine, an anticonvulsant with
primary effects on subcortical limbic structures, decreased the severity of
behavioral dyscontrol in 11 women with borderline personality disorder
significantly more than placebo. The authors emphasize the preliminary
nature of their findings and discuss alternative hypotheses regarding
mechanisms by which carbamazepine might influence behavioral
dyscontrol.
Abstract Teaser